About Index Trending news
Analyze
Pricing
Pluristem

Pluristem

Pluristem

A bio-therapeutics company developing a pipeline of products derived from human placenta - a non-controversial adult stem cell source.

Elsewhere

Contributors to this profile

Alexa global traffic share

Twitter followers

Latest funding Show all
Post-IPO equity
$15,000,000
Post-IPO equity
$30,000,000
Innovative Medical Management
Employees

Unknown size

Locations
HQ
Headquarters
$15,000,000 Post-IPO equity
NoCamels - Israeli Innovation News

Pluristem Raises $15M, Can-Fite $5M

$3,300,000 Grant
Pharmaceutical Processing

Pluristem Secures $3.3M for R&D

NoCamels

Pluristem Gets $3.3M Grant From Government

$2,900,000 Grant
pluristem

Pluristem Therapeutics Inc. - June 17, 2015 (2)